Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Aurora, Colorado

This page shows live ClinicalTrials.gov search results for Aurora, Colorado, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
7450
Shown on this page
12
Current sort
Recently updated
Location scope
Aurora, CO
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Aurora, Colorado. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 589–600 of 7,450 matching trials in Aurora, CO.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Aurora

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others

NCT01193075
View directory record Official record
Conditions
Charcot Marie Tooth Disease
Interventions
Not listed
Lead sponsor
Michael Shy
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2030
U.S. locations
18
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 15, 2026, 8:38 AM EST
Recruiting Phase 2 Interventional

Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

NCT07318597
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH)
Interventions
REGN13335, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 15, 2026, 8:38 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Neurophysiologic Biomarkers in Rett Syndrome

NCT05932589
View directory record Official record
Conditions
Rett Syndrome, RTT, Rett Syndrome, Atypical
Interventions
EEG and Auditory and Visual Evoked Potentials (AEP and VEP), Clinical assessment
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 18 Years · Female only
Enrollment
222 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Brookline, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 15, 2026, 8:38 AM EST
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia

NCT07304089
View directory record Official record
Conditions
Dystonia
Interventions
VIM0423, VIM0423 Placebo
Drug
Lead sponsor
Vima Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
41
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Sun City, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 15, 2026, 8:38 AM EST
Active, not recruiting Phase 3 Interventional

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

NCT06864988
View directory record Official record
Conditions
Macular Neovascularization Secondary to Age-Related Macular Degeneration
Interventions
4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Biological
Lead sponsor
4D Molecular Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
90
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Springdale, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 15, 2026, 8:38 AM EST
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

NCT07100106
View directory record Official record
Conditions
Breast Cancer
Interventions
GDC-4198, Giredestrant, Abemaciclib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
33
States / cities
Huntsville, Alabama • Tucson, Arizona • Duarte, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 15, 2026, 8:38 AM EST
Completed Phase 2 Interventional

A Phase 2b Study of Zagociguat in Patients With MELAS

NCT06402123
View directory record Official record
Conditions
Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Interventions
zagociguat 15mg, zagociguat 30mg, Placebo
Drug
Lead sponsor
Tisento Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
La Jolla, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 8:38 AM EST
Active, not recruiting Phase 3 Interventional

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia

NCT05426733
View directory record Official record
Conditions
Biliary Atresia
Interventions
Odevixibat
Drug
Lead sponsor
Albireo, an Ipsen Company
Industry
Eligibility
Not listed
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
10
States / cities
Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 8:38 AM EST
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome

NCT05419492
View directory record Official record
Conditions
Dravet Syndrome
Interventions
ETX101
Drug
Lead sponsor
Encoded Therapeutics
Industry
Eligibility
6 Months to 17 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
11
States / cities
San Francisco, California • Aurora, Colorado • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 8:38 AM EST
Terminated Phase 4 Interventional Accepts healthy volunteers

Efficacy and Safety of NVX-CoV2705

NCT07086222
View directory record Official record
Conditions
COVID-19, Sars-CoV-2 Infection
Interventions
NVX-CoV2705, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
50 Years to 65 Years
Enrollment
6,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
99
States / cities
Athens, Alabama • Birmingham, Alabama • Gadsden, Alabama + 88 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 8:38 AM EST
Recruiting Phase 3 Interventional

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

NCT07097142
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Mitomycin, Positron Emission Tomography, Survey Administration, Ultrahypofractionated Radiation Therapy
Procedure · Drug · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
258
States / cities
Fairbanks, Alaska • Fort Smith, Arkansas • Little Rock, Arkansas + 196 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 8:38 AM EST
Active, not recruiting Phase 3 Interventional Results available

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

NCT01674140
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, everolimus, exemestane, goserelin acetate, letrozole, leuprolide acetate, tamoxifen citrate, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1,939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1454
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 888 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 15, 2026, 8:38 AM EST